Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amylyx Pharmaceuticals (AMLX) Other Accumulated Expenses: 2021-2022

Historic Other Accumulated Expenses for Amylyx Pharmaceuticals (AMLX) over the last 1 years, with Dec 2022 value amounting to $1.0 million.

  • Amylyx Pharmaceuticals' Other Accumulated Expenses rose 289.53% to $1.0 million in Q4 2022 from the same period last year, while for Dec 2022 it was $1.0 million, marking a year-over-year increase of 289.53%. This contributed to the annual value of $1.0 million for FY2022, which is 289.53% up from last year.
  • Latest data reveals that Amylyx Pharmaceuticals reported Other Accumulated Expenses of $1.0 million as of Q4 2022, which was up 182.30% from $356,000 recorded in Q3 2022.
  • Amylyx Pharmaceuticals' 5-year Other Accumulated Expenses high stood at $1.0 million for Q4 2022, and its period low was $258,000 during Q4 2021.
  • Over the past 2 years, Amylyx Pharmaceuticals' median Other Accumulated Expenses value was $439,000 (recorded in 2022), while the average stood at $518,600.
  • Data for Amylyx Pharmaceuticals' Other Accumulated Expenses shows a peak YoY spiked of 289.53% (in 2022) over the last 5 years.
  • Quarterly analysis of 2 years shows Amylyx Pharmaceuticals' Other Accumulated Expenses stood at $258,000 in 2021, then soared by 289.53% to $1.0 million in 2022.
  • Its Other Accumulated Expenses stands at $1.0 million for Q4 2022, versus $356,000 for Q3 2022 and $535,000 for Q2 2022.